Dapivirine
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Dapivirine
- Molecular weight
- 329.41
- Structure (SMILES)
- Cc1cc(C)c(Nc2ccnc(Nc3ccc(C#N)cc3)n2)c(C)c1
- aids 105293
- AIDS-105293
- DAPIRING (Dapivirine) 25mg Vaginal Ring
- dapiring dapivirine 25mg vaginal ring
- dapivirina
- Dapivirina
- dapivirine
- Dapivirine
- dapivirine (TMC120) vaginal gel
- dapivirine (TMC120) vaginal ring
- dapivirine [INN]
- DAPIVIRINE [USAN]
- Dapivirine [WHO-DD]
- dapivirine gel
- Dapivirine gel
- Dapivirine gel (0.05%)
- dapivirine gel 0 05
- dapivirine inn
- dapivirine maraviroc vaginal ring
- dapivirine tmc120 vaginal gel
- dapivirine tmc120 vaginal ring
- dapivirine usan
- dapivirine who dd
- Dapivirine-Maraviroc Vaginal Ring
- gel 02
And 10 more, listed on the interactive page.
- ATC classification codes
- G01AX17
Sources for recorded values
- CAS registry numbers
- 244767-67-7
- ChEMBL ID
- CHEMBL70663
- InChIKey
- ILAYIAGXTHKHNT-UHFFFAOYSA-N
- PubChem compound IDs
- 214347
- FDA ingredient codes (UNII)
- TCN4MG2VXS
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -vir-
Mechanisms of action
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
- Action type
- Inhibitor
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Protein identifier
- Q72547
Open Targets mechanisms
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
- Action type
- Inhibitor
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Condition
- HIV Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- HIV Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Acquired Immunodeficiency Syndrome
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000765
- Subject identifier
- D000163
- Condition identifier
- EFO_0000180
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000765
- Condition identifier
- MONDO_0005109
- Highest recorded phase
- 1
- NCT00303576
- NCT00304642
- NCT00304668
- NCT00332995
- NCT00469768
- NCT00613249
- NCT00700284
- NCT00917891
- NCT01071174
- NCT01144013
- NCT01144676
- NCT01242579
- NCT01337570
- NCT01337583
- NCT01363037
- NCT01539226
- NCT01548560
- NCT01617096
- NCT01731574
- NCT02010593
- NCT02028338
- NCT02658227
- NCT02808949
- NCT02847286
- NCT02858024
And 14 more, listed on the interactive page.
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 73.63
- Calculated partition coefficient (ALogP)
- 4.76
- Calculated partition coefficient (XLogP)
- 4.8
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 25
- Molecular formula
- C20H19N5
- Monoisotopic mass
- 329.16404563
- Natural product
- Yes
- Recorded assays
- 662
- Active assays
- 186
Active assay types
- Confirmatory
- Anti-HIV Agents
Solubility
- Median
- 0.15
- Mean
- 0.15
- Minimum
- 0.15
- Maximum
- 0.15
- Unit
- ug/mL
- Assays
- 3
- Standard deviation
- 0.00000000000000000801234
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Related records
Trials (39)
- A Pharmacokinetic Study of Dapivirine Vaginal Rings in Belgium
- A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings
- A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium
- A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel
- A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in Belgium
- A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in South Africa
- A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
- A Safety Study to Assess the Delivery of Dapivirine From a Matrix Vaginal Ring
- A Study to Assess the Pharmacokinetics of Dapivirine (TMC120) Vaginal Microbicide Gel
- A Trial In Healthy HIV-Negative Women To Assess The Effect Of Menses And Tampon Use On The Pharmacokinetics Of Dapivirine, Delivered By Dapivirine Vaginal Ring-004, Containing 25 Mg Of Dapivirine
- An Expanded Safety Study of Dapivirine Gel 4759 in Africa
- An Expanded Safety Study of Dapivirine Gel 4789 in Africa
- Assessing the Safety of Dapivirine Gel and Film Formulations
- Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study
- Dapivirine Gel Rectal Safety and PK Study
- DDI Potential: Dapivirine Vaginal Ring and Miconazole Nitrate
- Expanded Use PK of Dapivirine Vaginal Ring
- Feasibility Study of a Vaginal Ring for Delivery of TMC120 (Dapivirine)
- Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT
- Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures
In development for (2)
- AIDS Phase 1
- HIV infectious disease Phase 3